SecBot SecBot
SECBOTREPLAY Home › Report › XENE

XENE · Xenon Pharmaceuticals presented positive Phase 3 X-TOLE2 and long-term…

Xenon Pharmaceuticals Inc. · PRESS-RELEASE filed Apr 19, 2026 at 18:00 ET

At the news

BULLISHIMPACT 8/10

PRESS-RELEASE filed Apr 19, 2026 at 18:00 ET

Xenon Pharmaceuticals presented positive Phase 3 X-TOLE2 and long-term open-label data for azetukalner in focal onset seizures at the AAN 2026 meeting, showing statistically significant and durable seizure reduction, with nearly 40% of long-term patients achieving at least 12 months of seizure freedom. The company plans to submit an NDA to the FDA in Q3 2026.

  • Azetukalner 25 mg achieved a 53.2% reduction in monthly seizure frequency vs. 10.4% for placebo (p<0.0001) in the Phase 3 X-TOLE2 trial.
  • Long-term data from the X-TOLE OLE study show 38.2% of patients treated for ≥48 months achieved at least 12 months of seizure freedom.
  • Azetukalner demonstrated consistent safety with low rates of serious adverse events (5.6% in 25 mg group vs. 2.4% placebo).
  • Xenon plans to submit an NDA for azetukalner in epilepsy to the FDA in Q3 2026.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access